A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions

Major Depressive Disorder (MDD)

Interventions

DRUG

KH607 tablets

oral 30mg , once daily for 14 days

DRUG

placebo

oral, once daily for 21 days

DRUG

KH607 tablets

oral 20mg, once daily for 21 days

DRUG

KH607 tablets

oral 30mg, once daily for 21 days